Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary has obtained the drug registration certificate for Compound Electrolyte Injection.
Jin Pharmaceutical Industry (600488.SH) announced that its subsidiary, Hubei Jin Pharmaceutical Industry Co., Ltd., has received the "Drug Registration Certificate" for Compound Electrolyte Injection, approved and issued by the National Medical Products Administration. This drug can serve as a source of water and electrolytes and as an alkalizing agent. The acquisition of this drug registration certificate enhances the company's formulation product portfolio and is expected to have a positive impact on the company's expansion into the domestic formulation market and improvement of its performance.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Hubei Tianjin Tianyao Pharmaceuticals Co., Ltd., has recently received the "Drug Registration Certificate" for its compound electrolyte injection issued by the National Medical Products Administration. This drug can serve as a source of hydration and electrolyte supplementation as well as an alkalizing agent. The acquisition of this drug registration certificate enhances the company's formulation product line and is expected to have a positive impact on the company's expansion into the domestic formulation market and the improvement of its performance.
Related Articles
Earnings Preview | The Battle of the AI Chip Titans Escalates! AMD (AMD.US) Earnings Report Will Test the Strength of NVIDIA Corporation as a "Challenger"
CHINA CINDA (01359) issued a profit warning, expecting a decrease of approximately 60% to 70% in net profit attributable to shareholders for the interim period compared to the same period last year.
Apeloa Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Jitai Technology.
Earnings Preview | The Battle of the AI Chip Titans Escalates! AMD (AMD.US) Earnings Report Will Test the Strength of NVIDIA Corporation as a "Challenger"
CHINA CINDA (01359) issued a profit warning, expecting a decrease of approximately 60% to 70% in net profit attributable to shareholders for the interim period compared to the same period last year.
Apeloa Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Jitai Technology.
RECOMMEND
